Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Borderline Resectable Carcinoma · Unresectable Cancer · Esophageal Squamous Cell Carcinoma (ESCC) · Immune Checkpoint Inhibitor · Chemotherapy · Radiotherapy · Tislelizumab

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital, Shantou University Medical College, Shantou, Guangdong, China
Contact: Study coordinator (Chuangzhen Chen) · czchen2@stu.edu.cn · +86 13923995569

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Lung Cancer Non-Small Cell Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE2

Freiburg im Breisgau, Germany · Stuttgart, Germany

CEB-01 in Locally Resectable Pancreatic Cancer

Pancreatic Carcinoma

Abroad (travel likely)RecruitingPHASE2

Barcelona, Spain · Madrid, Spain

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

HCC

Abroad (travel likely)RecruitingPHASE2

Jinan, China